tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ENGN Stock Latest News

enGene price target lowered to $9 from $10 at UBS
The FlyenGene price target lowered to $9 from $10 at UBS
1d ago
ENGN
enGene price target lowered to $30 from $33 at Oppenheimer
PremiumThe Fly
enGene price target lowered to $30 from $33 at Oppenheimer
13d ago
ENGN
enGene price target lowered to $27 from $30 at Guggenheim
PremiumThe Fly
enGene price target lowered to $27 from $30 at Guggenheim
14d ago
ENGN
Buy Rating on enGene: Detalimogene’s Competitive Efficacy, Community-Friendly Delivery, and Regulatory Momentum Support $25 Target
PremiumRatings
Buy Rating on enGene: Detalimogene’s Competitive Efficacy, Community-Friendly Delivery, and Regulatory Momentum Support $25 Target
14d ago
ENGN
enGene Strengthens Balance Sheet as Bladder Cancer Gene Therapy Nears Key 2026 Milestones
PremiumCompany Announcements
enGene Strengthens Balance Sheet as Bladder Cancer Gene Therapy Nears Key 2026 Milestones
15d ago
ENGN
enGene reports Q1 EPS (44c), consensus (57c)
PremiumThe FlyenGene reports Q1 EPS (44c), consensus (57c)
15d ago
ENGN
enGene to Highlight Genetic Medicine Pipeline at Series of Investor Conferences
Premium
Company Announcements
enGene to Highlight Genetic Medicine Pipeline at Series of Investor Conferences
1M ago
ENGN
enGene files $400M mixed securities shelf
Premium
The Fly
enGene files $400M mixed securities shelf
1M ago
ENGN
enGene to Spotlight Bladder Cancer Gene Therapy at Guggenheim Biotech Summit 2026
PremiumCompany Announcements
enGene to Spotlight Bladder Cancer Gene Therapy at Guggenheim Biotech Summit 2026
2M ago
ENGN
enGene CEO to Highlight Genetic Medicine Strategy at Guggenheim Biotech Summit 2026
PremiumCompany Announcements
enGene CEO to Highlight Genetic Medicine Strategy at Guggenheim Biotech Summit 2026
2M ago
ENGN
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
2M ago
ENGN
MNPR
Spotify upgraded, Pinterest downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Spotify upgraded, Pinterest downgraded: Wall Street’s top analyst calls
2M ago
ALC
DGX
enGene initiated with a Buy at Jefferies
PremiumThe FlyenGene initiated with a Buy at Jefferies
2M ago
ENGN
enGene Secures Expanded $125 Million Debt Facility to Advance Bladder Cancer Gene Therapy
Premium
Company Announcements
enGene Secures Expanded $125 Million Debt Facility to Advance Bladder Cancer Gene Therapy
2M ago
ENGN
3 ‘Strong Buy’ Stocks to Buy Today,12/26/2025, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today,12/26/2025, According to Top Analysts
3M ago
ENGN
NVDA
3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
3M ago
NOW
ENGN
Reaffirming Buy on enGene: Strengthened LEGEND Phase 2 Data, Robust Cash Runway to 2028, and Path to 2026 BLA for Detalimogene
PremiumRatings
Reaffirming Buy on enGene: Strengthened LEGEND Phase 2 Data, Robust Cash Runway to 2028, and Path to 2026 BLA for Detalimogene
3M ago
ENGN
enGene (ENGN): Advancing Detalimogene Toward Commercialization in NMIBC with Practical Competitive Edge Justifies Buy Rating and $25 Target
PremiumRatings
enGene (ENGN): Advancing Detalimogene Toward Commercialization in NMIBC with Practical Competitive Edge Justifies Buy Rating and $25 Target
3M ago
ENGN
enGene: Strong LEGEND Data, Regulatory Tailwinds, and Solid Cash Runway Support Buy Rating and $19 Target
PremiumRatings
enGene: Strong LEGEND Data, Regulatory Tailwinds, and Solid Cash Runway Support Buy Rating and $19 Target
3M ago
ENGN
enGene reports FY25 EPS $2.29 vs. $1.46 last year
PremiumThe FlyenGene reports FY25 EPS $2.29 vs. $1.46 last year
3M ago
ENGN
Strong Buy Rating for enGene Driven by Regulatory Advancements and Market Readiness of Detalimogene
Premium
Ratings
Strong Buy Rating for enGene Driven by Regulatory Advancements and Market Readiness of Detalimogene
4M ago
ENGN
enGene’s Detalimogene Chosen for FDA Manufacturing Pilot Program
Premium
Company Announcements
enGene’s Detalimogene Chosen for FDA Manufacturing Pilot Program
4M ago
ENGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >